FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization

Stock News

04/10

FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1173461200"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173461200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173461200?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173461200","market":"nz","top_or_hot":-1,"title":"FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization","media":"Stock News","content":"<p>FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-10 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1173461200","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173461200","pubTimestamp":1775814265,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0239":"医药制造","BK0183":"MSCI概念","BK1191":"制药","BK1515":"抗疫概念","02196":"复星医药","BK0188":"融资融券","BK1593":"医美概念股","BK0012":"证金概念","BK0096":"民营医院","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队"},"translate_title":"复星医药氟比洛芬酯注射液获上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug registration of Flurbiprofen Axetil Injection. The approved indication is for postoperative and cancer pain management. This drug is a chemically synthesized product independently developed by the group. As of March 2026, the group's cumulative R&D investment in this drug amounted to approximately RMB 34 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Flurbiprofen Axetil Injection in China (excluding Hong Kong, Macao, and Taiwan) reached about RMB 1.158 billion in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}